Navigation Links
Schering-Plough Addresses Major Milestones and Challenges in,Treatment of Patients With Chronic Hepatitis C

Highlights key data at the 42nd annual meeting of the European Association for the Study of the Liver (EASL)

KENILWORTH, N.J., April 11, 2007 /PRNewswire-FirstCall/ -- Schering-Plough Corporation reaffirms its commitment to advancing the science and treatment of chronic hepatitis C virus (HCV) infection with several key data presentations at the European Association for the Study of the Liver (EASL) 42nd annual meeting in Barcelona, Spain, April 11-15. A total of 38 data presentations highlighting Schering-Plough hepatitis medications will be presented at EASL 2007.

Among these are several studies with PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin) combination therapy, a current standard of care in the treatment of chronic hepatitis C, evaluating how results at important treatment milestones can help physicians make informed treatment decisions.

Schering-Plough also is exploring novel therapeutic approaches, both through targeted internal research programs and strategic collaborations. Chief among these efforts is boceprevir (SCH 503034), Schering-Plough's investigational oral HCV protease inhibitor currently in Phase II clinical development for treating chronic hepatitis C. Individual in vitro studies of boceprevir in combination with investigational oral HCV polymerase inhibitors from Wyeth/ViroPharma and Idenix/Novartis have been completed and will be presented at EASL.

"Schering-Plough is proud of its long-term role in introducing innovative treatments to the field of hepatitis," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "Our vision with PEGINTRON, our cornerstone HCV therapy, and ongoing work with boceprevir, our investigational oral HCV protease inhibitor, is to continue to advance the science and deliver additional treatment options for patients with hepatitis C infection."

Numerous studi
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
3. New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women
4. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
5. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
6. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
7. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
8. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
9. Major Manufacturer of Unapproved and Adulterated Drugs
10. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
Post Your Comments:
(Date:1/6/2009)...r maintaining a healthy immune system , , PURCH...shed study in Nutrition and Cancer (60(5), 643-6... Osaka, Japan has shown that AHCC (Active Hexose C...creasing the number of dendritic cells (DCs). DCs ...r presenting foreign substances to other immune sy...
(Date:1/6/2009)...wswire/ -- Cequent Pharmaceuticals, a pioneer in t...ased treatments to prevent and treat human disease...d a successful toxicology study of its candidate C... targeting the primary oncogene (beta-catenin, CTN...is an inherited gastrointestinal disease that caus...
(Date:1/5/2009)...ewswire-FirstCall/ -- Micromet, Inc.,(Nasdaq: M...l, proprietary,antibodies for the treatment of ca...des an outlook on key events anticipated for the y...n update on its research and development,programs...16, 2009: Update on several preclinical BiTE antib...
(Date:12/29/2008)...wire-USNewswire/ -- The winner of the 2008 Award f...ounced today by Dr. Peter G. Goldschmidt, Presiden... , , The winner of the annual award was the ...-- for its best practice " IND Regulatory and Mo...nhanced human subjects protection, 2) improved dat...
Breaking Medicine Technology:Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 3Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 52008 Human Research Protection Award Recipients Announced 2Depressed Moms Kids at Higher Injury Risk 7613 1Depressed Moms Kids at Higher Injury Risk 7613 2Fry Construction Is Featured in Key Industry Publication 7610 1Fry Construction Is Featured in Key Industry Publication 7610 2InvoiceCHECK Cuts Prescription Benefit Waste 7606 1InvoiceCHECK Cuts Prescription Benefit Waste 7606 2DenteMax Forms Business Alliance With MEDILINQ 7602 1DenteMax Forms Business Alliance With MEDILINQ 7602 2
...lood Pressure in Obese and,Non-Obese Hypertensive ...all/ -- Forest,Laboratories, Inc. today presented ...oled analysis of nebivolol, a selective beta,1-blo...review by,the U.S. Food and Drug Administration (F...he two clinical studies show that,nebivolol demons...
... and 40/25 mg/day and Amlodipine +,Benazepril 5/20...,Hypertension Twenty-Second Annual Scientific Meet...- New data,presented today at the American Society... Meeting (ASH 2007) in Chicago,demonstrated that t...medoxomil/hydrochlorothiazide) was associated with...
Other Medicine Technology:Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 2Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 3Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure,as Long-Term Monotherapy and in Combination Therapy 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 2Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 3Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 4Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 5Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 6Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 7Benicar HCT Reductions in Seated Systolic Blood Pressure for Stage,2 Patients Compared With Amlodipine + Benazepril 8
(Date:1/8/2009)...bad cholesterol more effectively than Zocor , ... nearly a year of review, U.S. health officials sa...of the controversial cholesterol-lowering drug Vyt...aid there was no significant difference in carotid...and patients taking the drug Zocor. , But, the ...
(Date:1/8/2009).... 8 Hanger Orthopedic Gr...at throughout the fourth quarter of 2008 it acquir...cky Mountain Orthotic-Prosthetics Center, Riessen,...Coast Orthotics & Prosthetics, and Orthopedic ...dd patient care centers to existing markets in Mai...
(Date:1/8/2009)...Jan. 8 Medivation, Inc.,..., M.D., president and chief,executive officer, wi...re,Conference on Wednesday, January 14, at 10:00 ... in San Francisco. , Dr. Hung will provide ...pment programs for Dimebon for Alzheimer,s and Hun...
(Date:1/8/2009).... 8 A new educational W...dance on drugs, biological products and medical de...Quality,s Centers for Education and Research on Th...of more than a dozen leading research centers nati...formation Network ( CHAIN ) http://www.chainonlin...
Breaking Medicine News(10 mins):Health News:FDA Backs Cholesterol Drug Vytorin 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference 2Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2
...at should be welcome news for tens of thousands of...ing homes are modernising and entering into tie-up... the growing trend in medical tourism. Half a doz...e up in a year, in addition to scores of smaller g...
...mical component extracted from the cannabis, or ma...ach cramping after eating, according to a study pr... the American College of Gastroenterology. The stu...and placebo on colonic motility and sensation in h...
...rs working in Iraq admit that more than half of th... medical equipment and more experienced staff and ...sim Al Sheibani and colleagues say that as the vio...y is that they cannot treat many of the victims. ...
...ding to the researchers in the U.S., a supplement ...ction of stress linked to metabolic syndrome, a co... diabetes and heart disease. Metabolic syndrome c...on, and unstable glucose and insulin metabolism an...
Other Medicine News:Health News:Agra Hospitals Modernise to Promote Medical Tourism 2Health News:Cinnamon extract in reduction of risk of metabolic syndrome 2
Fixed chair back and armrests, electric lift with 8" (20.3cm) stroke, foot pedal control, choice of upholstery colors. Optional features: 15 tilt mechanism and footrest, locking rotation, sliding arm
Complete with headrest, armrests, footrest and foot switch.
...Large hinged footstep can support patient's full w...ired. Hydraulic base. Patients may be raised and l...chair back or optional corded foot switch. Dual ro... to swivel the chair 330 without changing position...
Heine Beta 200 Streak Retinoscope 3.5v w/Twist Lock for Welch-Allyn style handles.
Medicine Products: